Newsletter | November 18, 2020

11.18.20 -- Can Valneva Do What SmithKlineBeecham Couldn't?

Featured Editorial
Industry Insights
Validation Or Qualification: What’s The Difference?

What is the difference between qualification and validation? This question comes up frequently with both internal and external clients. 

Is Your Biologics At Risk For Protein Aggregation? Part 2

The manufacture of sterile injectables is fraught with risk, especially when it comes to protein aggregation in biologics drugs. We offer steps you can take to help prevent aggregation.

Analytical Instrumentation: Advancing A CDMO’s Capabilities

To serve client needs as pharma tech advances, a CDMO must know when to acquire new tech, increase overall instrument capacity, and maintain existing validated instrumentation.

Answering Today’s Pharma Dilemma Of Build Or Buy

A new business and operating model may address the build or buy dilemma, offering an innovative and agile way to manage demand uncertainty and reduce the risks associated with early investment decisions.

Key Concepts Driving The Future Of Single-Use In Biopharma Production

This article discusses four topics related to single-use bioprocessing that are commonly cited by end users as amenable to future development. 

Enabling Perfusion Processes With Cell Retention Technologies

In this white paper, we explore various strategies for the intensification of upstream perfusion processes with cell retention technologies and the viability of each solution.

Case Study For Developability Assessment Of Three Therapeutic Antibodies

This poster reviews studies for three monoclonal antibody drug candidates utilizing a panel of small scale, fast, and predictive tests used to evaluate therapeutic antibodies’ developability.

DSD For The icIEF Assay Development Of Antibodies, Therapeutic Proteins

Here we describe a design of experiment (DOE) approach using a definitive screening design (DSD) model to optimize the icIEF development of a glycosylated protein transferrin and an IgG1 monoclonal antibody (mAb).

Cost Savings And Speed: The Untapped Value Of A Single-Source Solution

Small and emerging companies face significant challenges in today’s market. This calls for an alternative solution to help them achieve success.

Practical Tips To Develop A Lentivirus Packaging Cell Line

CAR-T therapies are expensive, and lentiviral vectors production represents a large portion of the costs. These practical tips guide efficient development of a lentivirus packaging cell line.

Laboratory Freezer For Single-Use Technology
Biopharma manufacturers are increasingly using single-use tech for storage, shipping, and transfer of substances. Abandoning cost-intensive and bulky platforms can save considerable amounts of money.

Tuesday, November 24, 2020 | 10:00 a.m. EST

This webinar will discuss the use of advanced colonic targeting strategies for oral drug products and other microbiome therapeutics. We will review some of the latest pH, time, and microbial dependent drug delivery technologies that can enable precise targeting of the colon. Options to enhance the solubility of drug products for colonic applications will also be discussed.

Life Science Leader Magazine

Have you heard of Life Science Leader?
Check it out today for access to candid interviews with top-tier executives on how they do business.